Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement?
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605478902 | ||
| 003 | CHVBK | ||
| 005 | 20210128100407.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150701xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10741-015-9479-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10741-015-9479-6 | ||
| 245 | 0 | 0 | |a Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? |h [Elektronische Daten] |c [Marinus Borgdorff, Michael Dickinson, Rolf Berger, Beatrijs Bartelds] |
| 520 | 3 | |a Right ventricular (RV) failure determines outcome in patients with pulmonary hypertension, congenital heart diseases and in left ventricular failure. In 2006, the Working Group on Cellular and Molecular Mechanisms of Right Heart Failure of the NIH advocated the development of preclinical models to study the pathophysiology and pathobiology of RV failure. In this review, we summarize the progress of research into the pathobiology of RV failure and potential therapeutic interventions. The picture emerging from this research is that RV adaptation to increased afterload is characterized by increased contractility, dilatation and hypertrophy. Clinical RV failure is associated with progressive diastolic deterioration and disturbed ventricular-arterial coupling in the presence of increased contractility. The pathobiology of the failing RV shows similarities with that of the LV and is marked by lack of adequate increase in capillary density leading to a hypoxic environment and oxidative stress and a metabolic switch from fatty acids to glucose utilization. However, RV failure also has characteristic features. So far, therapies aiming to specifically improve RV function have had limited success. The use of beta blockers and sildenafil may hold promise, but new therapies have to be developed. The use of recently developed animal models will aid in further understanding of the pathobiology of RV failure and development of new therapeutic strategies. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a Pressure overload |2 nationallicence | |
| 690 | 7 | |a Congenital heart diseases |2 nationallicence | |
| 690 | 7 | |a Pulmonary hypertension |2 nationallicence | |
| 690 | 7 | |a Pulmonary artery banding |2 nationallicence | |
| 690 | 7 | |a MRI |2 nationallicence | |
| 690 | 7 | |a Pressure-volume analysis |2 nationallicence | |
| 690 | 7 | |a CHD : Congenital heart diseases |2 nationallicence | |
| 690 | 7 | |a Ees : End-systolic elastance |2 nationallicence | |
| 690 | 7 | |a Eed : End-diastolic elastance |2 nationallicence | |
| 690 | 7 | |a ERA : Endothelin receptor antagonists |2 nationallicence | |
| 690 | 7 | |a FAO : Fatty acid oxidation |2 nationallicence | |
| 690 | 7 | |a LV : Left ventricle |2 nationallicence | |
| 690 | 7 | |a MCT : Monocrotaline |2 nationallicence | |
| 690 | 7 | |a PAB : Pulmonary artery banding |2 nationallicence | |
| 690 | 7 | |a PDE5 : Phosphodiesterase 5 |2 nationallicence | |
| 690 | 7 | |a PDK : Pyruvate dehydrogenase kinase |2 nationallicence | |
| 690 | 7 | |a PKG : Protein kinase G |2 nationallicence | |
| 690 | 7 | |a PH : Pulmonary hypertension |2 nationallicence | |
| 690 | 7 | |a RAAS : Renin−angiotensin aldosterone system |2 nationallicence | |
| 690 | 7 | |a RV : Right ventricle |2 nationallicence | |
| 700 | 1 | |a Borgdorff |D Marinus |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | |
| 700 | 1 | |a Dickinson |D Michael |u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | |
| 700 | 1 | |a Berger |D Rolf |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | |
| 700 | 1 | |a Bartelds |D Beatrijs |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | |
| 773 | 0 | |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/4(2015-07-01), 475-491 |x 1382-4147 |q 20:4<475 |1 2015 |2 20 |o 10741 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10741-015-9479-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10741-015-9479-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Borgdorff |D Marinus |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dickinson |D Michael |u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Berger |D Rolf |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bartelds |D Beatrijs |u Department of Pediatrics, Center for Congenital Heart Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Heart Failure Reviews |d Springer US; http://www.springer-ny.com |g 20/4(2015-07-01), 475-491 |x 1382-4147 |q 20:4<475 |1 2015 |2 20 |o 10741 | ||